Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting
Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials
V. Strand¹, S. Ahadieh², J. French³, J. Geier⁴, S. Krishnaswami⁵, S. Menon⁵, T. Checchio², R. Riese⁶ and J. Gomez-Reino⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pharmacometrics, Pfizer Inc, Groton, CT, ³Metrum Research Group, Tariffville, CT, ⁴Pfizer Inc, New York, NY, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Groton, CT, ⁷Hospital Clinico, Universitario de Santiago, Santiago, Spain
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…
Abstract Number: 1831 • 2014 ACR/ARHP Annual Meeting
Monitoring Patients with Rheumatoid Arthritis in Routine Care – Experiences from a Treat-to-Target Strategy Using the Danbio Registry
Merete Lund Hetland¹, Dorte Vendelbo Jensen² and Niels Steen Krogh³, ¹On behalf of all Depts of Rheumatology in Denmark, DANBIO, Glostrup Hospital, Glostrup, Denmark, ²DANBIO, Glostrup, Denmark, ³ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: Monitoring patients with rheumatoid arthritis (RA) in clinical practice with regular assessment of disease activity (e.g. DAS28) is recommended as a part of a…
Abstract Number: 1046 • 2014 ACR/ARHP Annual Meeting
Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients
Wei Yu¹, Wenfeng Tan² and Miaojia Zhang³, ¹Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, nanjing, China, ²Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, ³the first affliated hospital with nanjing medical univercity, nanjing, China
Background/Purpose We previously reported that adiponectin (AD) is highly expressed in the inflammatory joint of rheumatoid arthritis (RA) patients and closely correlated with progressive bone…
Abstract Number: 457 • 2014 ACR/ARHP Annual Meeting
First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Kazuhiko Yamamoto¹, Hajime Goto², Kenzo Hirao³, Atsuo Nakajima⁴, Hideki Origasa⁵, Nobuhiro Takagi⁶, Minako Tomobe⁷ and Kyoichi Totsuka⁸, ¹Allergy & Rheumatology, Univ Tokyo Gr School of Med, Tokyo, Japan, ²Fukujuji Hospital, Tokyo, Japan, ³Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Rheumatology, Tokyo Metropolitan Police Hospital, Tokyo, Japan, ⁵Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁶Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ⁷Pharmacovigilance, Chugai Pharmaceutical, Tokyo, Japan, ⁸Kitatama Hospital, Tokyo, Japan
Background/Purpose: To evaluate the long-term safety of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Japan. Methods: In…
Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
B Combe¹, DJ Veale², R Burgos-Vargas³, G Szűcs⁴, M Leirisalo-Repo⁵, R Yao⁶, S Huyck⁶, R Lyu⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Monpellier University Hospital, Montpellier, France, ²Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, ³Cliditer S.A. de C.V. and Hospital General de Mexico, Mexico City, Mexico, ⁴University of Debrecen Faculty of Medicine, Debrecen, Hungary, ⁵Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸MSD Belgium, Brussels, Belgium
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…
Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Rossella Reggia¹, Franco Franceschini¹, Angela Tincani² and Ilaria Cavazzana¹, ¹AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…
Abstract Number: 1042 • 2014 ACR/ARHP Annual Meeting
IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts
Christelle Darrieutort-Laffite^1,2, Marie Astrid Boutet¹, Mathias Chatelais¹, Regis Brion³, Frederic Blanchard¹, Dominique Heymann³ and Benoit Le Goff^1,2, ¹Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, INSERM, UMR 957, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France, ³Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, INSERM, UMR 957, Nantes, France
Background/Purpose Macrophages and synovial fibroblasts (SF) are two major cells implicated in the pathogenesis of rheumatoid arthritis (RA). They can interact in the synovial micro-environment…
Abstract Number: 411 • 2014 ACR/ARHP Annual Meeting
ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis
Yemil Atisha-Fregoso¹, Hilda Fragoso-Loyo², Juan Jakez-Ocampo³, Guadualupe Lima⁴, Miguel Baños², Virginia Pascual-Ramos⁵, Irazu Contreras-Yañez² and Luis Llorente⁶, ¹Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁴Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico, ⁵Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose ABCB1 (P-gp) and ABCG2 (BCRP) are part of the adenine triphosphate (ATP)-binding cassette (ABC) transporter proteins. These proteins mediate efflux of drugs from inside…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients
Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
Abstract Number: 403 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Juan Chen¹ and Dana P. Ascherman², ¹Rheumatology, The First Afflicted Hospital of Xiamen University,, Xiamen,, China, ²Medicine/Rheumatology, University of Miami, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Asymptomatic, subclinical RA-associated…
Abstract Number: 2877 • 2013 ACR/ARHP Annual Meeting
Potential Of Integrating Human Genetics and Electronic Medical Records For Drug Discovery: The Example Of TYK2 and Rheumatoid Arthritis
Dorothee Diogo¹, Katherine P. Liao², Robert S. Fulton³, Robert R. Graham⁴, Jing Cui⁵, Jeffrey D. Greenberg⁶, Stephen Eyre⁷, John Bowes⁸, Annette T. Lee⁹, Dimitrios A. Pappas¹⁰, Joel M. Kremer¹¹, Anne Barton⁷, Marieke J.H. Coenen¹², Xavier Mariette¹³, Corrine Richard-Miceli¹⁴, Helena Canhão¹⁵, João E. Fonseca¹⁶, Niek de Vries¹⁷, Fina Kurreeman¹⁸, Ted R. Mikuls¹⁹, Yukinori Okada¹, Isaac Kohane²⁰, Joshua C. Denny²¹, Jane Worthington²², Soumya Raychaudhuri¹, Timothy W. Behrens²³, Michael F. Seldin²⁴, Peter K. Gregersen²⁵, Elaine R. Mardis³ and Robert M. Plenge²⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³The Genome Institute, Washington University School of Medicine, Saint Louis, MO, ⁴ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶NYU Hospital for Joint Diseases, New York, NY, ⁷Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁹Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ¹¹Center for Rheumatology, Albany Medical College, Albany, NY, ¹²Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹⁴Hôpital Bicêtre, Université Paris-sud, Paris, France, ¹⁵Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹⁷Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²⁰on behalf of i2b2 ; Brigham and Women's Hospital, Boston, MA, ²¹Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, ²²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ²³Genentech, Inc, South San Francisco, CA, ²⁴Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA, ²⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Human genetics has the potential to identify promising drug targets for complex traits such as rheumatoid arthritis (RA). Genes with a series of disease-associated…
Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Matthew M. Seavey¹, Linglong Zou², Adam Clarke³, Anthony G. Doyle³, Roberta Weiss⁴, Aric Orbach⁵, Brad McIntyre⁶ and Merav Bassan⁷, ¹Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., West Chester, PA, ²GB&T, Teva Biopharmaceuticals, Rockville, MD, ³Discovery Biologics, Teva Pharmaceuticals, Inc., Sydney, Australia, ⁴Clinical Development, Teva Pharmaceuticals, Inc., Frazer, PA, ⁵Nonclinical Development, Pharmacology, Teva Pharmaceuticals, Inc., Netanya, Israel, ⁶Formulation, Teva Pharmaceuticals, Inc., West Cheater, PA, ⁷Teva R&D - Innovative Project Leadership, Teva Pharmaceuticals, Inc., Netanya, Israel
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
Abstract Number: 1432 • 2013 ACR/ARHP Annual Meeting
The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Patrice Cacoub Sr.³, Thomas Bardin⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁵Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁶Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹¹Rheumatology Department, CHU of ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ¹⁷Rheumatology Departement, Bicêtre University Hospital, Paris, France
Background/Purpose: Serious infections in patients with rheumatoid arthritis (RA) treated with rituximab (RTX) are slightly more frequent in common practice than in clinical trials. Morevover,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].